ZYMEWORKS INC. (ZYME) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.13B; Additional Paid in Capital, Common StockUSD $116.45M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-6.69M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.13B; Additional Paid in Capital, Common StockUSD $107.53M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-6.57M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.11B; Additional Paid in Capital, Common StockUSD $114.63M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-6.08M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.09B; Additional Paid in Capital, Common StockUSD $111.49M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-6.05M.
ZYMEWORKS INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Retired, Cost Method, Amount USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.13B | $116.45M | $-6.69M | $-1.17B | $80.37M | (m) | 3 month · $11.11M | (m) |
| 2026-03-31 | $0.00 | $1.13B | $107.53M | $-6.57M | $-1.07B | $163.59M | (m) | 3 month · $6.88M | (m) |
| 2025-12-31 | $0.00 | $1.11B | $114.63M | $-6.08M | $-953.16M | $268.50M | 12 month · $41.70M | 12 month · $27.07M | (m) |
| 2025-09-30 | $0.00 | $1.09B | $111.49M | $-6.05M | $-886.47M | $320.06M | 3 month · $16.22M | 3 month · $6.38M | (m) |
| 2025-06-30 | $0.00 | $1.07B | $109.24M | $-6.34M | $-850.65M | $334.51M | (m) | 3 month · $5.77M | (m) |
| 2025-03-31 | $0.00 | $1.02B | $154.22M | $-6.41M | $-852.97M | $324.97M | (m) | 3 month · $6.79M | (m) |
| 2024-12-31 | $0.00 | $1.02B | $152.25M | $-6.95M | $-830.34M | $338.77M | 12 month · $30.05M | 12 month · $16.72M | (m) |
| 2024-09-30 | $0.00 | $1.01B | $148.30M | $-6.00M | $-797.83M | $366.98M | 3 month · $21.12M | 3 month · $4.03M | (m) |
| 2024-06-30 | $0.00 | $1.01B | $147.34M | $-7.90M | $-746.78M | $406.16M | (m) | 3 month · $4.89M | (m) |
| 2024-03-31 | $0.00 | $1.00B | $143.14M | $-7.72M | $-709.09M | $438.00M | (m) | 3 month · $3.44M | (m) |
| 2023-12-31 | $0.00 | $997.23M | $142.27M | $-6.60M | $-677.44M | $464.81M | (m) | 12 month · $8.20M | 12 month · $49.86M |
| 2023-09-30 | $0.00 | $932.14M | $154.11M | $-8.30M | $-662.96M | $424.34M | (m) | 3 month · $2.69M | (m) |
| 2023-06-30 | $0.00 | $929.40M | $152.26M | $-7.81M | $-634.27M | $448.92M | (m) | 3 month · $742.00K | (m) |
| 2023-03-31 | $0.00 | $900.49M | $152.68M | $-5.94M | $-583.12M | $473.54M | (m) | 3 month · $2.20M | (m) |
| 2022-12-31 | $0.00 | $886.32M | $151.61M | $-6.66M | $-558.76M | $492.96M | (m) | 12 month · $9.52M | (m) |
| 2022-09-30 | (m) | $885.35M | $169.26M | $-6.66M | $-868.19M | $179.76M | (m) | 3 month · $4.38M | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | $222.28M | (m) | 3 month · $4.45M | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | $282.44M | (m) | 3 month · $-2.93M | (m) |
| 2021-12-31 | $0.00 | $741.15M | $197.71M | $-6.66M | $-683.10M | $249.09M | (m) | 12 month · $38.27M | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | $278.93M | (m) | 3 month · $10.33M | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | $321.47M | (m) | 3 month · $11.09M | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | $377.14M | (m) | 3 month · $8.53M | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | $409.92M | (m) | 12 month · $26.95M | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $245.68M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |